ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AMS Advanced Medical Solutions Group Plc

185.80
-0.80 (-0.43%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions Group Plc LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.80 -0.43% 185.80 185.60 187.00 188.80 185.20 187.40 272,263 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Plastics,resins,elastomers 126.21M 15.89M 0.0732 25.44 404.45M

Advanced Medical Solutions Grp PLC IDE received for LiquiBand Fix8 in US (8802Y)

14/05/2019 7:00am

UK Regulatory


Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Advanced Medical Solutions Charts.

TIDMAMS

RNS Number : 8802Y

Advanced Medical Solutions Grp PLC

14 May 2019

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

IDE received for LiquiBand Fix8 in US

   -     Clinical study to start imminently for LiquiBand(R) Fix8(TM) in the US 

Winsford, UK, 14 May 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that the Company has received Investigational Device Exemption (IDE) for the LiquiBand(R) Fix8(TM) device in the US. This exemption by the FDA now allows AMS to begin the planned patient clinical trial, with first patient enrolment before the end of May, in line with previous guidance at the time of the full year results.

In the clinical study, LiquiBand(R) Fix8(TM) will be used in laparoscopic hernia repair treatments and 284 patients are due to be enrolled with the last patient expected by the end of 2019. The study will close after the final patient has received 12 months follow up and the Company intends to report on this data thereafter.

An IDE allows an investigational device to be used in order to collect safety and effectiveness data required to support a premarket approval (PMA). The approval process in the US for LiquiBand(R) Fix8(TM) is expected to complete by the second half of 2020.

Commenting on the announcement, Chris Meredith, CEO of AMS, said: "LiquiBand(R) Fix8(TM)has been growing sales strongly and receiving very positive feedback from surgeons in the European market and we are delighted that we can now start a study with our proprietary device that could benefit patients in the US market. Innovation is at the heart of AMS and this is just one example of our devices that helps patients, surgeons and healthcare payors. We look forward to reporting on further development with LiquiBand(R) Fix8(TM) as it grows sales and receives further approvals."

- End -

For further information, please visit www.admedsol.com or contact:

 
 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 
                                                             545508 
 Chris Meredith, Chief Executive Officer 
 
 Consilium Strategic Communications            Tel: +44 (0) 20 3709 
                                                               5700 
 Mary-Jane Elliott / Matthew Neal / Nicholas 
  Brown / Olivia Manser 
 
 Investec Bank PLC (NOMAD & Broker)            Tel: +44 (0) 20 7597 
                                                               5970 
 Daniel Adams / Patrick Robb / Gary Clarence 
 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand(R) , LiquiBand(R) Fix 8(TM), RESORBA(R) and ActivHeal(R) as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 630 employees. For more information, please see www.admedsol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCZMGMKVFGGLZM

(END) Dow Jones Newswires

May 14, 2019 02:00 ET (06:00 GMT)

1 Year Advanced Medical Solutions Chart

1 Year Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart

1 Month Advanced Medical Solutions Chart

Your Recent History

Delayed Upgrade Clock